Allgens(SH:688613)2024-04-25 09:01Financial Performance - The company's operating revenue for 2023 was CNY 226,475,894.98, a decrease of 7.68% compared to CNY 245,305,139.72 in 2022[20]. - Net profit attributable to shareholders for 2023 was CNY 54,231,840.71, down 43.04% from CNY 95,217,271.83 in 2022[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 25,766,199.74, a decline of 67.82% from CNY 80,059,300.23 in 2022[20]. - The net cash flow from operating activities decreased by 49.36% to CNY 51,678,545.68 from CNY 102,054,525.91 in 2022[20]. - The basic earnings per share for 2023 was CNY 0.41, a decrease of 42.25% from CNY 0.71 in 2022[21]. - The company achieved a total revenue of CNY 226.48 million, a year-on-year decrease of 7.68%[81]. - The net profit attributable to shareholders was CNY 54.23 million, down 43.04% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 25.77 million, a decline of 67.82%[81]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 0.61 per 10 shares, totaling RMB 8,133,333.37, which represents 15% of the net profit attributable to shareholders[5]. - The board of directors has approved the profit distribution plan, pending approval at the annual shareholders' meeting[5]. - The company has a clear cash dividend policy that prioritizes sustainable returns to shareholders while ensuring operational stability[169]. - The company has not made any adjustments to its established cash dividend policy during the reporting period[174]. Research and Development - The R&D expenditure as a percentage of operating revenue was 20.09% in 2023, down from 23.42% in 2022[21]. - The company achieved a total R&D investment of ¥45,504,233.46 in the reporting period, a decrease of 20.81% compared to ¥57,461,479.48 in the previous year[62]. - The company received 16 invention patents during the reporting period, bringing the total to 70 patents[59]. - The company is leading a project for the development of personalized cranial biomimetic composite repair materials, which has been approved for the "14th Five-Year" national key R&D plan[60]. - The company has established a joint research center with Tsinghua University to enhance the development of high-performance biomaterials[48]. Market Expansion and Sales - The company successfully expanded its market presence by adding over 280 new distributors and developing more than 200 new hospitals, resulting in a positive sales trend[34]. - The company focuses on high-end biomedical materials and related medical devices, with a marketing network covering over 900 hospitals in China[38]. - The company is focusing on expanding its market presence through a distribution model, with a dedicated marketing and sales department to manage product sales and support[125]. - The company plans to enhance R&D investment and capabilities to accelerate the conversion of research results into high-quality products, aiming to expand product variety and upgrade existing products[132]. Governance and Compliance - The company has received a standard unqualified audit opinion from Lixin Certified Public Accountants[5]. - The company has established a robust internal control system to ensure effective business operations and protect asset integrity, while continuously improving governance practices[37]. - The company emphasizes the protection of shareholder rights and adheres to relevant laws and regulations to enhance corporate governance[196]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation and decision-making processes[136]. Risks and Challenges - The company has not reported any significant risks that could materially affect its operations during the reporting period[4]. - The company faces risks related to product registration renewals and potential delays in new product approvals due to regulatory scrutiny[75]. - Subsidiaries have not yet achieved profitability, indicating potential short-term financial risks if business plans are not executed as expected[76]. Environmental and Social Responsibility - The company is committed to fulfilling its social responsibilities and enhancing its ESG practices in line with regulatory expectations[133]. - The company has implemented energy-saving measures in equipment procurement to reduce electricity consumption[191]. - The company produced general industrial waste and hazardous waste during its operations, but does not engage in high-risk or heavily polluting activities[186]. - The company has made donations totaling 1 million yuan for community support initiatives[194]. Employee Management and Compensation - The total number of employees in the parent company and major subsidiaries is 202, with 123 in the parent company and 79 in subsidiaries[164]. - The company maintains a structured salary system based on job responsibilities, performance, and market competitiveness to attract and retain talent[165]. - Total compensation for core technical personnel at the end of the reporting period was 418.54 million[154]. - The company has established a performance evaluation mechanism for senior management linked to operational and profitability targets[181].